The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

Ítems similars

• The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
  per: Muhammad Rauzan, et al.
  Publicat: (2017-01-01)
• The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
  per: Novotny-Diermayr, V, et al.
  Publicat: (2012)
• Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells
  per: Okabe, Seiichi, et al.
  Publicat: (2013)
• The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia
  per: Ko, Tun Kiat, et al.
  Publicat: (2015)
• HDAC INHIBITORS POTENTIATE THE ACTIVITY OF THE BCR/ABL KINASE INHIBITOR KW-2449 IN IMATINIB-SENSITIVE OR -RESISTANT BCR/ABL(+) LEUKEMIA CELLS IN VITRO AND IN VIVO
  per: Nguyen, Tri, et al.
  Publicat: (2011)